secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-278804
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra expands RASP platform to CNS diseases; reproxalap manufacturing inspections closed
--------------------------------------------------------------------------------

- ADX-248 preclinical results in Parkinson's & ALS models showed improved grip strength, balance, and CNS biomarkers.
- FDA completed reproxalap drug substance and product facility inspections; closed with VAI designation, no further action.
- Aldeyra expanded RASP platform to central nervous system diseases; ADX-248 is oral next-gen RASP modulator.
- Reproxalap is a first-in-class investigational candidate for dry eye disease signs and symptoms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000119312525278804/0001193125-25-278804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000119312525278804/aldx-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-278804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer